Novartis sells off dry eye disease med Xiidra, other ophthalmology assets to Bausch + Lomb for $2.5B
Novartis is passing off the dry eye disease drop Xiidra to eye health specialist Bausch + Lomb in a $2.5 billion deal, another step in the company's overhaul as it focuses on five core areas. Bausch + ...
Bausch & Lomb BLCO announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback